Viatris (VTRS) Competitors $9.18 +0.25 (+2.80%) Closing price 04:00 PM EasternExtended Trading$9.17 -0.01 (-0.11%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTRS vs. ARGX, ONC, BNTX, TEVA, SMMT, ITCI, GMAB, RDY, ASND, and QGENShould you be buying Viatris stock or one of its competitors? The main competitors of Viatris include argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry. Viatris vs. Its Competitors argenex BeOne Medicines BioNTech Teva Pharmaceutical Industries Summit Therapeutics Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Ascendis Pharma A/S Qiagen Viatris (NASDAQ:VTRS) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment. Which has better valuation & earnings, VTRS or ARGX? argenex has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViatris$14.74B0.73-$634.20M-$3.17-2.90argenex$2.25B14.71$833.04M$16.2133.47 Which has more risk and volatility, VTRS or ARGX? Viatris has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Comparatively, argenex has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500. Is VTRS or ARGX more profitable? argenex has a net margin of 40.20% compared to Viatris' net margin of -26.45%. Viatris' return on equity of 16.20% beat argenex's return on equity.Company Net Margins Return on Equity Return on Assets Viatris-26.45% 16.20% 7.01% argenex 40.20%16.15%14.33% Does the media prefer VTRS or ARGX? In the previous week, argenex had 12 more articles in the media than Viatris. MarketBeat recorded 18 mentions for argenex and 6 mentions for Viatris. Viatris' average media sentiment score of 0.65 beat argenex's score of 0.53 indicating that Viatris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive argenex 4 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in VTRS or ARGX? 79.9% of Viatris shares are owned by institutional investors. Comparatively, 60.3% of argenex shares are owned by institutional investors. 0.1% of Viatris shares are owned by insiders. Comparatively, 2.4% of argenex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts prefer VTRS or ARGX? Viatris presently has a consensus target price of $10.40, indicating a potential upside of 13.29%. argenex has a consensus target price of $729.93, indicating a potential upside of 34.56%. Given argenex's stronger consensus rating and higher possible upside, analysts plainly believe argenex is more favorable than Viatris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viatris 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80argenex 0 Sell rating(s) 1 Hold rating(s) 17 Buy rating(s) 2 Strong Buy rating(s) 3.05 Summaryargenex beats Viatris on 12 of the 17 factors compared between the two stocks. Get Viatris News Delivered to You Automatically Sign up to receive the latest news and ratings for VTRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VTRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTRS vs. The Competition Export to ExcelMetricViatrisMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.48B$7.40B$5.48B$8.94BDividend Yield5.38%2.79%5.38%4.12%P/E Ratio-2.9028.0626.2219.73Price / Sales0.7332.91405.80109.12Price / Cash1.7522.0136.4957.06Price / Book0.596.617.925.37Net Income-$634.20M$230.16M$3.15B$248.34M7 Day Performance2.57%5.00%0.95%1.25%1 Month Performance4.79%7.79%5.25%5.41%1 Year Performance-13.31%36.28%32.63%18.06% Viatris Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTRSViatris3.0192 of 5 stars$9.18+2.8%$10.40+13.3%-16.0%$10.48B$14.74B-2.9032,000ARGXargenex4.3094 of 5 stars$540.76-0.3%$709.18+31.1%+28.2%$33.02B$2.25B33.361,599Trending NewsAnalyst ForecastONCBeOne Medicines3.4756 of 5 stars$257.51+4.2%$319.00+23.9%N/A$28.22B$3.81B-69.2211,000Gap UpBNTXBioNTech2.4524 of 5 stars$103.01-3.3%$137.86+33.8%+32.5%$24.76B$2.98B-30.306,772TEVATeva Pharmaceutical Industries4.0453 of 5 stars$16.96+0.1%$24.44+44.1%+3.1%$19.45B$16.54B-14.7536,830SMMTSummit Therapeutics2.4827 of 5 stars$20.39-0.8%$35.09+72.1%+172.8%$15.14B$700K-59.97110Analyst UpgradeITCIIntra-Cellular Therapies0.9026 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.8855 of 5 stars$20.68-2.3%$39.17+89.4%-17.8%$13.26B$3.12B11.752,682High Trading VolumeRDYDr. Reddy's Laboratories3.0071 of 5 stars$15.31+0.5%$16.95+10.7%-1.4%$12.78B$3.81B23.2027,811Positive NewsASNDAscendis Pharma A/S3.5114 of 5 stars$175.78-0.6%$220.67+25.5%+26.6%$10.75B$393.54M-27.991,017QGENQiagen3.7375 of 5 stars$46.72-0.1%$47.74+2.2%+20.3%$10.39B$2.00B117.145,765Dividend Announcement Related Companies and Tools Related Companies argenex Alternatives BeOne Medicines Alternatives BioNTech Alternatives Teva Pharmaceutical Industries Alternatives Summit Therapeutics Alternatives Intra-Cellular Therapies Alternatives Genmab A/S Alternatives Dr. Reddy's Laboratories Alternatives Ascendis Pharma A/S Alternatives Qiagen Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTRS) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viatris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viatris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VTRS Stock Alerts